Home
About Idogen
Idogen in brief
Management team
Board of directors
Scientific advisory board
Business concept
Horizon 2020
Career
R&D
Idogen´s technology
Research overview
Project portfolio
Research collaborations
Scientific publications
Investors
Stock information
Owners
Certified advisor
Analysts
Financial reports
Financial calendar
Presentations
Upcoming events
Investors contact
News & Media
News
Interviews
Interview with Neil Thomas, Chief Business Officer in Idogen
Interview with Karin Hoogendoorn, Board member in Idogen
Interview with Steven Glazer, Chief Medical Officer in Idogen
Contact us
Search
Menu
Financial reports
2019
Interim report Q1 2019
2018
Annual report 2018
Year-end report 2018
Interim report Q3 2018
Interim report Q2 2018
Interim report Q1 2018
2017
Annual Report 2017
Year-end report 2017
Interim report Q3 2017 (in Swedish)
Interim report Q2 2017 (in Swedish)
Interim report Q1 2017 (in Swedish)
2016
Annual report 2016 (in Swedish)
Year-end report 2016 (in Swedish)
Interim report Q3 2016 (in Swedish)
Teaser 2016 (in Swedish)
Interim report Q2 2016 (in Swedish)
Interim report Q1 2016 (in Swedish)
2015
Annual report 2015 (in swedish)
Year-end report 2015 (in Swedish)
Interim report Q3 2015 (in Swedish)
Half year report 2015 (in Swedish)
Prospectus 2015 (in Swedish)
2014
Annual report 2014 (in Swedish)
2013
Annual report 2013 (in Swedish)
Idogen develops tolerogenic cell therapy – individualised treatment for each patient
Scroll to top
